Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries

Author:

Sing Chor-WingORCID,Lin Tzu-Chieh,Bartholomew Sharon,Bell J Simon,Bennett Corina,Beyene Kebede,Bosco‐Lévy Pauline,Chan Amy Hai Yan,Chandran Manju,Cheung Ching-Lung,Doyon Caroline Y,Droz-Perroteau Cécile,Ganesan Ganga,Hartikainen Sirpa,Ilomaki Jenni,Jeong Han Eol,Kiel Douglas P,Kubota Kiyoshi,Lai Edward Chia-Cheng,Lange Jeff,Lewiecki E Michael,Liu Jiannong,Man Kenneth K CORCID,Mendes de Abreu MirhelenORCID,Moore Nicolas,O’Kelly James,Ooba Nobuhiro,Pedersen Alma B,Prieto-Alhambra DanielORCID,Shin Ju-YoungORCID,Sørensen Henrik T,Tan Kelvin Bryan,Tolppanen Anna-Maija,Verhamme Katia M CORCID,Wang Grace Hsin-Min,Watcharathanakij Sawaeng,Zhao HongxinORCID,Wong Ian C K

Abstract

IntroductionHip fractures are associated with a high burden of morbidity and mortality. Globally, there is wide variation in the incidence of hip fracture in people aged 50 years and older. Longitudinal and cross-geographical comparisons of health data can provide insights on aetiology, risk factors, and healthcare practices. However, systematic reviews of studies that use different methods and study periods do not permit direct comparison across geographical regions. Thus, the objective of this study is to investigate global secular trends in hip fracture incidence, mortality and use of postfracture pharmacological treatment across Asia, Oceania, North and South America, and Western and Northern Europe using a unified methodology applied to health records.Methods and analysisThis retrospective cohort study will use a common protocol and an analytical common data model approach to examine incidence of hip fracture across population-based databases in different geographical regions and healthcare settings. The study period will be from 2005 to 2018 subject to data availability in study sites. Patients aged 50 years and older and hospitalised due to hip fracture during the study period will be included. The primary outcome will be expressed as the annual incidence of hip fracture. Secondary outcomes will be the pharmacological treatment rate and mortality within 12 months following initial hip fracture by year. For the primary outcome, crude and standardised incidence of hip fracture will be reported. Linear regression will be used to test for time trends in the annual incidence. For secondary outcomes, the crude mortality and standardised mortality incidence will be reported.Ethics and disseminationEach participating site will follow the relevant local ethics and regulatory frameworks for study approval. The results of the study will be submitted for peer-reviewed scientific publications and presented at scientific conferences.

Funder

Amgen

Publisher

BMJ

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3